{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"3.1"},{"groupId":"OG001","value":"17.9"},{"groupId":"OG002","value":"18.1"}]}],"title":"Week 12"},{"categories":[{"measurements":[{"groupId":"OG000","value":"7.9"},{"groupId":"OG001","value":"25.3"},{"groupId":"OG002","value":"24.2"}]}],"title":"Week 24"}],"denoms":[{"counts":[{"groupId":"OG000","value":"228"},{"groupId":"OG001","value":"229"},{"groupId":"OG002","value":"227"}],"units":"Participants"}],"description":"ACR70 Responder Index is composite of clinical, laboratory, and functional measures in RA. \"ACR70 Responder\" is a participant who has at least 70% improvement in both tender and swollen joint counts and in at least 3 of the following 5 criteria: Physician Global Assessment of Disease Activity, Patient's Global Assessment of Disease Activity, HAQ-DI, pain due to arthritis, and hsCRP. Participants with missing responses and participants who discontinue study or drug or are rescued before analysis timepoint are deemed non-responders.","groups":[{"description":"Placebo administered orally once daily through Week 24.\n\nParticipants continued to take background conventional disease-modifying antirheumatic drug (cDMARD) therapy throughout study.","id":"OG000","title":"Placebo"},{"description":"Baricitinib 2 mg administered orally once daily through Week 24.\n\nParticipants continued to take background cDMARD therapy throughout study.","id":"OG001","title":"Baricitinib 2 mg"},{"description":"Baricitinib 4 mg administered orally once daily through Week 24.\n\nParticipants continued to take background cDMARD therapy throughout study.","id":"OG002","title":"Baricitinib 4 mg"}],"paramType":"NUMBER","populationDescription":"mITT population: all randomized participants who received at least 1 dose of the study drug. Missing values due to discontinuation of study or drug, rescue, or missing data were imputed using NRI.","reportingStatus":"POSTED","timeFrame":"Week 12, Week 24","title":"Percentage of Participants Achieving American College of Rheumatology 70% (ACR70) Response","type":"SECONDARY","unitOfMeasure":"percentage of participants"}